Brady v. Bayer Corp.
26 Cal. App. 5th 1156
Cal. Ct. App. 5th2018Background
- Plaintiff Brady sued Bayer (maker of "One A Day" Vitacraves gummies) alleging labeling is misleading because the prominent brand "One A Day" implies one gummy is a full daily dose, while the back label (in small print) directs consumers to take two gummies daily.
- Claims: violations of the Consumer Legal Remedies Act (CLRA), Unfair Competition Law (UCL), and breach of express warranty (Com. Code § 2313).
- Trial court sustained Bayer's demurrer without leave to amend, relying on federal district decisions that held a reasonable vitamin consumer would read the back label/dosage.
- The Court of Appeal reversed, holding Brady pleaded viable claims that survive demurrer.
- Court emphasized that (1) reasonable consumers are not homogeneous; some rely on longstanding brand expertise, and (2) a front-label implication cannot be undone by minute back-label fine print.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether front label + brand name is misleading under UCL/CLRA | "One A Day" front label implies one gummy provides a daily dose; front contradicts back; likely to deceive | Reasonable consumers would read the back/ingredient and serving-size info; no deception as a matter of law | Survives demurrer: plausible likelihood to deceive; cannot decide as matter of law |
| Whether reasonable consumer standard requires back-label scrutiny | Many consumers reasonably rely on brand expertise rather than parsing supplement labels | Vitamin purchasers are sophisticated about aggregate nutrient amounts and will check serving size/ingredients | Court rejects as matter of law that all reasonable consumers scrutinize back labels; market is heterogeneous |
| Whether back label fine print cures an apparent front-label misrepresentation (front-back dichotomy) | Back directions are inconspicuous and contradict the front; ingredient panel cannot be used to negate front implication | Serving-size and supplement facts on back disclose truth, curing any confusion | Fine print insufficient to negate front implication at pleading stage; Williams v. Gerber principle applies |
| Breach of express/implied warranty (Com. Code §§2313, 2316, 10215) | Front label and "100 gummies" create an affirmation/description that becomes basis of bargain (implying 100 days); disclaimer/back print not conspicuous | Specific back-label disclosures displace inconsistent general front language under commercial code | Warranty claim survives: disclaimer on back not conspicuous; cannot as matter of law displace front implication |
Key Cases Cited
- Williams v. Gerber Prods. Co., 552 F.3d 934 (9th Cir. 2008) (front-label representations cannot be negated by conflicting back-panel disclosures at pleading stage)
- Clorox Co. v. Proctor & Gamble Commer. Co., 228 F.3d 24 (1st Cir. 2000) (brand/name may be misleading where necessary implication is literally false)
- Novartis Consumer Health, Inc. v. Johnson & Johnson-Merck Consumer Pharms. Co., 290 F.3d 578 (3d Cir. 2002) (trade name may convey implied efficacy or formulation promises that can be enjoined if false)
- Abbott Labs. v. Mead Johnson & Co., 971 F.2d 6 (7th Cir. 1992) (trade name can be misleading when it implies characteristics not present)
- National Nutritional Foods Assn. v. FDA, 504 F.2d 761 (2d Cir. 1974) (recognizes distinction between sophisticated and ordinary vitamin consumers; supports protecting ordinary consumers)
- Benson v. Kwikset Corp., 152 Cal.App.4th 1254 (Cal. Ct. App. 2007) (literal falsity or necessary implication from labeling can support consumer claims)